Literature DB >> 9355905

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

S E Lipshultz1, N Rifai, S E Sallan, S R Lipsitz, V Dalton, D B Sacks, M E Ottlinger.   

Abstract

BACKGROUND: Biochemical markers have not been routinely used in children at risk for myocardial damage. Yet, because of somatic growth and the duration of survival, a low level of myocardial damage may ultimately be of more consequence in children than in adults. METHODS AND
RESULTS: We investigated the utility of cardiac troponin T (cTnT) blood levels (CARDIAC T ELISA Troponin T, Boehringer Mannheim Corp) in 51 consecutively sampled patients from 1 day to 34 years of age (median=5.7 years) undergoing cardiovascular (n=19) or noncardiovascular (n=17) surgery or who received doxorubicin for acute lymphoblastic leukemia (ALL) (n=15). Minimum detectable cTnT elevations were 0.03 ng/mL. cTnT was measurable in children of all ages with myocyte damage. In patients who underwent cardiovascular surgery, a correlation was noted between a score of increasing surgical severity and the mean level of postoperative cTnT (r=.79, P<.0001). Postoperative cTnT levels were elevated in children who completed cardiovascular surgery with an open chest compared with those with a closed chest (P=.0083). In addition, cTnT levels before cardiovascular surgery predicted postoperative survival (P=.007). cTnT elevations were observed after initial doxorubicin therapy for ALL. The magnitude of elevation predicted left ventricular dilatation (r=.80 when variables were treated as continuous, P=.003) and wall thinning (r=.61, P=.044) 9 months later.
CONCLUSIONS: Elevations of blood cTnT in children relate to the severity of myocardial damage and predict subsequent subclinical and clinical cardiac morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355905     DOI: 10.1161/01.cir.96.8.2641

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

2.  Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

Authors:  David Ebb; Paul Meyers; Holcombe Grier; Mark Bernstein; Richard Gorlick; Steven E Lipshultz; Mark Krailo; Meenakshi Devidas; Donald A Barkauskas; Gene P Siegal; William Shay Ferguson; George Douglas Letson; Karen Marcus; Allen Goorin; Peter Beardsley; Neyssa Marina
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 3.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Authors:  Douglas B Sawyer; Xuyang Peng; Billy Chen; Laura Pentassuglia; Chee Chew Lim
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

4.  Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Authors:  Ana Barac
Journal:  Future Cardiol       Date:  2015-08-04

Review 5.  Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

6.  Early detection of anomalous origin of left coronary artery from the right pulmonary artery after successful repair of critical coarctation of the aorta.

Authors:  Levent Celik; Vera Becker; Dieter Hammel; Jan-Hendrik Nürnberg
Journal:  Pediatr Cardiol       Date:  2009-12-04       Impact factor: 1.655

Review 7.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

8.  Cardiac complications of chemotherapy: role of biomarkers.

Authors:  Alessandro Colombo; Maria T Sandri; Michela Salvatici; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

9.  Anthracycline cardiotoxicity: from bench to bedside.

Authors:  Luca Gianni; Eugene H Herman; Steven E Lipshultz; Giorgio Minotti; Narine Sarvazyan; Douglas B Sawyer
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 10.  The breast cancer patient in the cardioncology unit.

Authors:  Daniela Cardinale; Vincenzo Caruso; Carlo M Cipolla
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.